Coherus Oncology (CHRS) Total Debt: 2014-2025
Historic Total Debt for Coherus Oncology (CHRS) over the last 10 years, with Sep 2025 value amounting to $37.0 million.
- Coherus Oncology's Total Debt fell 19.34% to $37.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year decrease of 19.34%. This contributed to the annual value of $50.3 million for FY2024, which is 79.86% down from last year.
- Latest data reveals that Coherus Oncology reported Total Debt of $37.0 million as of Q3 2025, which was up 0.24% from $36.9 million recorded in Q2 2025.
- Over the past 5 years, Coherus Oncology's Total Debt peaked at $250.3 million during Q3 2023, and registered a low of $36.9 million during Q2 2025.
- In the last 3 years, Coherus Oncology's Total Debt had a median value of $63.0 million in 2025 and averaged $122.1 million.
- As far as peak fluctuations go, Coherus Oncology's Total Debt soared by 225.99% in 2022, and later plummeted by 81.69% in 2024.
- Quarterly analysis of 5 years shows Coherus Oncology's Total Debt stood at $75.5 million in 2021, then skyrocketed by 225.09% to $245.5 million in 2022, then rose by 1.75% to $249.8 million in 2023, then crashed by 79.86% to $50.3 million in 2024, then fell by 19.34% to $37.0 million in 2025.
- Its Total Debt was $37.0 million in Q3 2025, compared to $36.9 million in Q2 2025 and $63.0 million in Q1 2025.